Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. (EPRX.TO) Revenue
Annual & quarterly revenue history · segment & region breakdown
EPRX.TO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsEupraxia Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Eupraxia Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Eupraxia Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Eupraxia Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
EPRX.TO revenue · 4 questionsEPRX.TO's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Eupraxia Pharmaceuticals Inc. SEC filings · GAAP · Eupraxia Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026